| Literature DB >> 35449823 |
Jing Wang1,2, Yaxing Zhang3, Qiuyuan Wang2,4, Luyao Wang1,2, Peitong Zhang1.
Abstract
Objective: We aimed to analyze the possible molecular mechanism of Xihuang pill (XHP) in the treatment of pancreatic cancer based on methods of network pharmacology, molecular docking, and bioinformatics.Entities:
Year: 2022 PMID: 35449823 PMCID: PMC9017490 DOI: 10.1155/2022/4651432
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650
List of active ingredients in XHP.
| Herb | Mol ID | Molecule name | Targets |
|---|---|---|---|
| SHE XIANG | MOL001232 | Testosterone | 3 |
| MOL010919 | 17-Beta-estradiol | 38 | |
| MOL000737 | Morin | 6 | |
| MOL002361 | Estragole | 14 | |
| MOL004783 | N-Nonane | 2 | |
| MOL000953 | Cholesterol | 3 | |
| NIU HUANG | MOL008838 | methyl(4R)-4-[(3R,5S,7S,8 R,9S,10S,12S,13 R,14S,17 R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate | 2 |
| MOL008839 | Methyl desoxycholate | 3 | |
| MOL008845 | Deoxycholic acid | 4 | |
| MOL008846 | ZINC01280365 | 5 | |
| MOL000953 | CLR | 3 | |
| MOL000511 | Ursolic acid | 19 | |
| RU XIANG | MOL001215 | Tirucallol | 2 |
| MOL001241 | O-acetyl- | 1 | |
| MOL001243 | 3alpha-hydroxy-olean-12-en-24-oic-acid | 6 | |
| MOL001255 | Boswellic acid | 2 | |
| MOL001295 | Phyllocladene | 1 | |
| MOL000390 | Daidzein | 27 | |
| MO YAO | MOL001001 | Quercetin-3-O- | 3 |
| MOL001002 | Ellagic acid | 10 | |
| MOL001004 | Pelargonidin | 11 | |
| MOL001006 | Poriferasta-7,22e-dien-3beta-ol | 3 | |
| MOL001009 | Guggulsterol-VI | 1 | |
| MOL001013 | Mansumbinoic acid | 1 | |
| MOL001026 | Myrrhanol C | 4 | |
| MOL001028 | (8R)-3-oxo-8-hydroxy-polypoda -13E,17 E,21-triene | 2 | |
| MOL001029 | Myrrhanones B | 2 | |
| MOL001031 | Epimansumbinol | 4 | |
| MOL001033 | Diayangambin | 5 | |
| MOL001040 | (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl) chroman-4-one | 6 | |
| MOL001045 | (13E,17 E,21E)-8-hydroxypolypodo-13,17,21-trien-3-one | 2 | |
| MOL001046 | (13E,17 E,21E)-polypodo-13,17,21-triene-3,18-diol | 1 | |
| MOL001049 | 16-Hydroperoxymansumbin-13(17)-en-3 | 2 | |
| MOL001052 | Mansumbin-13(17)-en- 3,16-dione | 6 | |
| MOL001061 | (16S, 20R)-dihydroxydammar-24-en-3-one | 5 | |
| MOL001062 | 15 | 5 | |
| MOL001063 | 28-Acetoxy-15 | 4 | |
| MOL001095 | Isofouquierone | 2 | |
| MOL001126 | [(5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,9-tetrahydroisobenzofurano[6,5-f] [1,3] benzodioxol-8a-yl] acetate | 16 | |
| MOL001131 | Phellamurin_qt | 6 | |
| MOL001138 | (3R,20S)-3,20-dihydroxydammar- 24-ene | 6 | |
| MOL001156 | 3-Methoxyfuranoguaia-9- en-8-one | 9 | |
| MOL001175 | Guggulsterone | 5 | |
| MOL000358 | Beta-sitosterol | 21 | |
| MOL000449 | Stigmasterol | 23 | |
| MOL000490 | Petunidin | 7 | |
| MOL000098 | Quercetin | 55 | |
| MOL000988 | 4,17(20)-(cis)-pregnadiene-3,16-dione | 2 | |
| MOL000996 | Guggulsterol IV | 3 | |
| MOL001125 | Erlangerin B | 2 | |
| MOL001127 | Erlangerin D | 7 | |
| MOL000254 | Eugenol | 25 | |
| MOL000978 | Furanoeudesma- 1,4-diene-6-one | 11 |
Figure 1Venn diagram of intersection targets (PC: pancreatic cancer).
Figure 2Protein interaction diagram.
Key targets.
| Name | Closeness centrality | Degree | Betweenness centrality |
|---|---|---|---|
| TP53 | 0.85 | 42 | 0.068810131 |
| VEGFA | 0.836065574 | 41 | 0.056756149 |
| IL6 | 0.796875 | 38 | 0.05317606 |
| MAPK1 | 0.796875 | 38 | 0.043544924 |
| EGF | 0.784615385 | 37 | 0.037239889 |
| EGFR | 0.784615385 | 37 | 0.043334685 |
| JUN | 0.76119403 | 35 | 0.022646029 |
| MAPK8 | 0.76119403 | 35 | 0.024236994 |
| TNF | 0.739130435 | 33 | 0.01515152 |
| ESR1 | 0.739130435 | 33 | 0.043118785 |
| PTGS2 | 0.739130435 | 33 | 0.013562229 |
| IL1B | 0.728571429 | 32 | 0.012370454 |
| MMP2 | 0.718309859 | 31 | 0.010559301 |
| MAPK14 | 0.708333333 | 30 | 0.012303754 |
| CAT | 0.698630137 | 30 | 0.05575807 |
| CCL2 | 0.708333333 | 30 | 0.007732274 |
| MMP1 | 0.662337662 | 26 | 0.017930964 |
| MMP3 | 0.662337662 | 26 | 0.016948756 |
| MPO | 0.671052632 | 26 | 0.016875167 |
| IFNG | 0.671052632 | 26 | 0.006005576 |
| NGF | 0.662337662 | 25 | 0.006541835 |
| IL2 | 0.662337662 | 25 | 0.00545143 |
| CXCL12 | 0.653846154 | 25 | 0.004267719 |
| CXCR4 | 0.6375 | 23 | 0.003965538 |
| HMOX1 | 0.64556962 | 23 | 0.00604897 |
| PLAU | 0.62195122 | 21 | 0.001768495 |
| NOS2 | 0.593023256 | 17 | 7.63E-04 |
Figure 3Composition-key target network diagram.
Figure 4Key functional modules.
Figure 5Functional enrichment bubble diagrams: (a) Go - CC diagram; (b) GO - MF diagram; (c) GO - BP diagram; (d) KEGG diagram.
Figure 6MAPK signal pathway diagram.
Figure 7Expression level of key targets.
Figure 8Survival analysis of key targets.
Docking results of key active ingredients and key targets.
| Quercetin | 17-Beta-estradiol | Ursolic acid | Daidzein | |
|---|---|---|---|---|
| Vina score | Vina score | Vina score | Vina score | |
| EGFR | -8 | -8.8 | -8.3 | -7.8 |
| MAPK1 | -8.5 | -8.9 | -8.8 | -7.9 |
Figure 9Docking modes: (a) EGFR-quercetin; (b) EGFR-17-beta-estradiol; (c) EGFR-ursolic acid; (d) EGFR-daidzein; (e) MAPK1- quercetin; (f) MAPK1-17-beta-estradiol; (g) MAPK1-ursolic acid; (h) MAPK1- daidzein.